fbpx

Isodiol Subsidiary Expands National Footprint

Isodiol International Inc. subsidiary Kure Corp. is opening new brick and mortar locations to expand its footprint in the United States (US). Kure will also acquire existing vape stores and introduce its new Vape Pod concept.

Isodiol acquired 100% of Kure in May 2018 as part of a strategic plan to expand its customer base.

Kure is a leading specialty vape retailer that has retail locations all over the US. It specializes in vaporizers, e-cigarettes, e-juices, and related accessories. After partnering with Isodiol, Kure has expanded its portfolio by adding CBD products to its range.

For the recent expansion, Kure signed a representation agreement with Newmark Knight Frank (NKF), which is operated by the Newmark Group, Inc.

NKF is one of the world’s leading commercial real estate advisory firms. The Newmark Group has identified national real estate investment trusts (REITs), who will provide class A retail locations for the Kure Vape Pod.

The Kure Vape Pod is a vaporium that Kure has created with SG Blocks, Inc, a leading designer of container-based structures. Kure Vape Pods are made from repurposed shipping containers. They allow for the same experience as a Kure store but in an eco-friendlier way.

The initial plan is to roll out new stores in 10 cities in the US, but more locations will be announced soon. Currently, Kure has 12 locations in the US that average $900,000 in annual gross sales per location.

Moreover, Kure Corp. will add Isodiol cannabidiol (CBD) products, including the new Kathy Ireland Health and Wellness products in Q2 2018.

About Isodiol International Inc.

Isodiol is a market leader in pharmaceutical-grade phytochemical compounds and an industry leader in the development of CBD consumer products. It is one of the pioneers in the commercialization of 99%+ pure cannabinoids, microencapsulation, and nanotechnology.

The company also manufactures the highest-quality consumable and topical products for skin care and pain management.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and the expansion of its phytoceutical portfolio. Besides this, the company plans to aggressively expand into international markets like Latin America, Asia, and Europe.

Read more: ‘CBD: The Biotech Boom Investors Haven’t Woken Up To Yet’